IMUGENE CHART. TA only, page-173

Biotech is a slow burn industry. So best to let it takes its cause. The design phase of a clinical trial is so important as getting it wrong can be the difference between success and failure with the same set of results. We are blessed to have an amazing team at IMU that gives us faith. We are all getting excited as important decisions and results draw near. Best to relax and sit back and enjoy the ride ahead. Best not to have daily expectations on IMU and biotech stocks. Don't let the "tree shakers" obtain your shares. Patience with IMU should reward. Good luck all holders.